Scienture Holdings Inc Dossier
Qualitative Analysis
Business overview
Scienture Holdings, Inc. (NASDAQ: SCNX), formerly known as TRxADE Health, Inc., is a specialty pharmaceutical holding company focused on developing, commercializing, and distributing novel specialty products to satisfy unmet medical needs. Operating primarily through its wholly owned subsidiaries, Scienture, LLC and Integra Pharma Solutions, LLC, the company focuses on bridging gaps in patient treatment delivery systems, particularly in the cardiovascular (CVS) and central nervous system (CNS) therapeutic areas. Scienture's business model centers on selectively designed drug innovations that enhance the treatment experience and improve adherence journeys. Its lead commercial assets include Arbli™ (losartan potassium oral suspension), the first and only FDA-approved ready-to-use liquid formulation of losartan for hypertension, and REZENOPY® (naloxone HCl nasal spray 10mg), a high-strength emergency treatment for opioid overdose.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Scaling commercialization efforts for Arbli™ (losartan potassium) Oral Suspension and REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, supported by $11 million in non-dilutive debt financing secured in May 2026.
Expected impact: Aims to drive significant sales growth, with revenue forecast to grow more than 10-fold in fiscal 2026, positioning the company toward profitability in 2027.
Advancing clinical development of innovative product candidates in the R&D portfolio, including SCN-104 (drug-device combination for migraine), SCN-106 (potential biosimilar for thrombosis), and SCN-107 (long-acting injection suspension for postsurgical analgesia).
Expected impact: Achieve key clinical and regulatory milestones to bring new proprietary therapies to market.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides Scienture with exclusive U.S. rights to commercialize REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, while Summit Biosciences manufactures and commercially supplies the product.
Terms: Scienture owns the New Drug Application (NDA) and is responsible for sales, marketing, and distribution in the U.S. pending certain commercial obligations.